{"generic":"Technetium Tc 99m Sodium Pertechnetate","drugs":["TechneLite","Technetium Tc 99m Sodium Pertechnetate"],"mono":{"0":{"id":"930245-s-0","title":"Generic Names","mono":"Technetium Tc 99m Sodium Pertechnetate"},"1":{"id":"930245-s-1","title":"Dosing and Indications","sub":[{"id":"930245-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cystography, Detection of vesicoureteral reflux:<\/b> 18.5 to 37 megabecquerels (0.5 to 1 millicuries) direct instillation into bladder via urethral catheter followed by 200 mL sterile saline catheter flush<\/li><li><b>Radiography of nasolacrimal duct:<\/b> 3.7 megabecquerels (100 microcuries) MAX instilled as OPHTHALMIC drops via micropipette or similar method<\/li><li><b>Radionuclide salivary gland imaging procedure:<\/b> 37 to 185 megabecquerels (1 to 5 millicuries) IV<\/li><li><b>Radionuclide thyroid imaging:<\/b> 37 to 370 megabecquerels (1 to 10 millicuries) IV<\/li><\/ul>"},{"id":"930245-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Cystography, Detection of vesicoureteral reflux:<\/b> 18.5 to 37 megabecquerels (0.5 to 1 millicuries) direct instillation into bladder via urethral catheter followed by 200 mL sterile saline catheter flush<\/li><li><b>Radionuclide thyroid imaging:<\/b> 2.22 to 2.96 megabecquerels (60 to 80 microcuries)\/kg body weight IV<\/li><\/ul>"},{"id":"930245-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> start at low end of dosing range "},{"id":"930245-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cystography, Detection of vesicoureteral reflux<\/li><li>Radiography of nasolacrimal duct<\/li><li>Radionuclide salivary gland imaging procedure<\/li><li>Radionuclide thyroid imaging<\/li><\/ul>"}]},"3":{"id":"930245-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930245-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930245-s-3-10","title":"Precautions","mono":"<ul><li>children; radiation risks greater for children than adults due to greater absorption and longer life expectancy, particularly in younger children; benefit\/risk assessment for children must be considered<\/li><li>microbial growth; the eluate does not contain an antimicrobial agent; eluate should not be used after 12 hours from the time of generator elution<\/li><li>nasolacrimal imaging procedure; upon termination of the procedure, blowing nose and washing eyes with sterile distilled water or isotonic sodium chloride solution can minimize the radiation dose<\/li><li>radiopharmaceutical; may increase risk of cancer with long-term cumulative exposure; handle with care and use safety measures to reduce radiation exposure to personnel and patient<\/li><\/ul>"},{"id":"930245-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930245-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"5":{"id":"930245-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"930245-s-6","title":"Drug Name Info","sub":{"0":{"id":"930245-s-6-17","title":"US Trade Names","mono":"TechneLite<br\/>"},"2":{"id":"930245-s-6-19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"930245-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930245-s-7","title":"Mechanism Of Action","mono":"Sodium pertechnetate Tc 99m is a diagnostic radiopharmaceutical that distributes throughout both the circulatory system and various organs, thereby enabling radiographic imaging for specific blood pool, organ perfusion, and major vessel studies.<br\/>"},"8":{"id":"930245-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"930245-s-8-26","title":"Excretion","mono":"Renal: fraction promptly excreted after intravascular\/extracellular equilibrium <br\/>"}}},"9":{"id":"930245-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>use proper procedures for handling and disposal of radiopharmaceuticals<\/li><li>expiration of drug is not later than 12 hours after elution<\/li><li>if eluate is used to reconstitute a kit for preparation, the kit should not be used 12 hours after kit reconstitution takes place or after the expiration time on labeling for the prepared drug, whichever is earlier<\/li><li>wear waterproof gloves during handling procedure and perform all operations aseptically<\/li><li>remove needle seal from charge well; discard as radioactive waste<\/li><li>remove seal of eluant charge vial, swab, and insert vial into charge well, assuring firm insertion<\/li><li>open shield base and insert eluate collection vial, screw base back on securely, and swab exposed vial septum<\/li><li>remove vented needle cover from well and discard as radioactive waste<\/li><li>insert shielded collection vial in collect well, within elution commencing within 30 seconds<\/li><li>allow generator to elute at least 3 minutes after charge has drained, or for a total of 6 minutes<\/li><li>after elution, remove shield on collection vial<\/li><li>obtain the collect needle seal vial, swab the septum, and insert over the collection needle<\/li><li>attach appropriate radioactivity labels and do not use eluate later than 1 working day from time of elution (12 hours)<\/li><li>use a shielded syringe when introducing the drug solution into mixing vials<\/li><\/ul>"}}}